Colts Pass-Rusher Robert Mathis Gets Four-Game NFL Suspension

Photographer: Scott Halleran/Getty Images

Indianapolis Colts linebacker Robert Mathis said the positive test was the result of a prescribed fertility medication. Close

Indianapolis Colts linebacker Robert Mathis said the positive test was the result of a... Read More

Close
Open
Photographer: Scott Halleran/Getty Images

Indianapolis Colts linebacker Robert Mathis said the positive test was the result of a prescribed fertility medication.

Indianapolis Colts linebacker Robert Mathis, who led the National Football League with 19 1/2 quarterback sacks last season, received a four-game suspension for violating the league’s performance-enhancing drug policy.

Mathis, 33, said the positive test was the result of a prescribed fertility medication. While Mathis said his doctor said the medication wouldn’t cause a problem for NFL drug testing, he didn’t contact the NFL or players’ union to double-check before taking it at the end of last season.

“The union has worked very closely with me to present all of the facts and medical records for consideration of discipline that does not include a suspension because of the unique facts of my case, but the commissioner refused the request,” Mathis said yesterday in a statement.

A five-time Pro Bowl selection, Mathis and his wife had twins in 2012 and learned -- shortly after he took the fertility medication -- they’ll have another baby this year.

Mathis will miss games against the Denver Broncos, Philadelphia Eagles, Jacksonville Jaguars and Tennessee Titans. He’ll be eligible to return for the Oct. 5 game against the Baltimore Ravens.

“I hope that my fans will understand the unique circumstances involved here and continue to know that I am a man of integrity who would never intentionally circumvent the performance-enhancing substance policy agreed to by the NFL and my union,” Mathis said.

To contact the reporter on this story: Erik Matuszewski in New York at matuszewski@bloomberg.net

To contact the editors responsible for this story: Michael Sillup at msillup@bloomberg.net Dex McLuskey

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.